|July 29, 2014|
|08:32 EDT||XON||Intrexon enters into technology collaboration with animal health company|
Intrexon has further enhanced its collaboration with a global animal health company to enable remote access to Intrexon's suite of technologies via its groundbreaking BeyondBio platform.
News For XON From The Last 14 Days
|January 26, 2015|
|08:34 EDT||XON||Intrexon launches tender offer to acquire stake in Exemplar Genetics|
Subscribe for More Information
|January 22, 2015|
|07:27 EDT||XON||Intrexon 3.75M share Secondary priced at $27.00|
The deal size was reduced to $101M in common stock from $150M in common stock. JPMorgan and BofA/Merrill acted as joint book running managers for the offering.
|January 20, 2015|
|16:03 EDT||XON||Intrexon files to sell $150M in common stock|
Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments. J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. Jefferies is acting as a lead manager for the offering. Griffin Securities and Mizuho Securities are acting as co-managers for the offering.
|13:21 EDT||XON||CAR T-Cell therapy drug stocks down sharply following NY Times story|
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link